Glenn Heller, PhD

Attending Biostatistician

Office Phone




New York University

Current Research Interests

Research Papers
A selection of research papers by Glenn Heller
Learn more

Dr. Heller’s current research interests include the design and analysis of phase II clinical trials and the analysis of survival data. For the analysis of phase II studies, he has developed a test statistic that adjusts for patient risk and improves the accuracy of the test for treatment efficacy relative to conventional tests. In survival analysis, Dr. Heller has developed a new measure of predictive accuracy, based on the concept of explained randomness that can be applied to risk models with survival data. Dr. Heller is involved in the design and analysis of laboratory and clinical studies emanating from the Departments of Medicine, Pediatrics, and Surgery. He is the primary statistician for NIH grants in bone marrow transplantation and prostate cancer.


Heller G. A measure of explained risk in the proportional hazards model. Biostatistics 2011; (in press).

Heller G. Proportional hazards regression with interval censored data using an inverse probability weight. Lifetime Data Analysis 17:373-385, 2011.

Heller G. Smoothed Rank Regression with Censored Data. Journal of the American Statistical Association 102; 552-559, 2007.

Heller G, Qin J. Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject. Statistical Applications in Genetics and Molecular Biology. 6:Article 14, 2007.

Heller G. Power calculations for preclinical studies using a K-sample rank test and the Lehmann alternative hypothesis. Statistics in Medicine 25: 2543-2553, 2006.

Read more

  1. LaQuaglia M, Corbally M, Heller G, Exelby P, Brennan M.  Recurrence and morbidity in differentiated thyroid carcinoma in children.  Surgery 1988; 104:1149-1156.

  2. Ghavimi F, Mandell LR, Heller G, Hajdu SI, Exelby P. Prognosis in childhood rhabdomyosarcoma of the extremity. Cancer 1989; 64:2233-2237.

  3. Keever CA, Small TM, Flomenberg N, Heller G, Pekle K, Black P, Pecora A, Gillio A, Kernan N, O’Reilly RJ.  Immune reconstitution following bone marrow transplantation:  comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 1989; 73:1340-1350.

  4. Kernan N, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenberg N, Burns J, Dupont B, Collins NH, O’Reilly RJ.   Graft failure following T cell depleted HLA identical marrow transplants for Leukemia I: Analysis of risk factors and results of secondary transplants.  Blood 1989; 74:2227-2236.

  5. LaQuaglia M, Ghavimi F, Heller G, Harr H, Mandell L, Corbally  M, Hajdu S, Exelby P.  Mortality in pediatric Paratesticular Rhabdomyosarcoma: a multivariate analysis.  J  Urol 1989; 142:473-478

  6. Berman E, Heller G, Kempin S, Gee T, Clarkson B.  Incidence of Response and long term follow up in patients with hairy cell leukemia treated with recombinant interferon Alfa-2a.  Blood 1990; 75:839-845.

  7. Heller G, Simonoff J.  A comparison of estimators for regression with a censored response variable. Biometrika 1990; 77:515-520.

  8. Incefy GS, Flomenberg N, Heller G, Kernan N, Brochstein J, Kirkpatrick D, Kapoor N, O’Reilly R.  Appearance of thymulin in plasma follows lymphoid chimerism and precedes development of immunity in patients with lethal combined immunodeficiency transplanted with T cell-depleted haploidentical marrow.  Transplantation 1990; 50:55-61.

  9. Kushner BH, Gulati SC, O’Reilly RJ, Heller G, Cheung NKV.  Autografting with bone marrow exposed to repeated multiple courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophosphamide in vitro. Med Pediatr Oncol 1990; 18:454-458.

  10. Small TN, Keever CA, Weiner-Fedus S, Heller G, O’Reilly J, Flomenberg N.  B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation:  a recapitulation of normal B-cell ontogeny.  Blood 1990; 76:1647-1656.

  11. Berman E, Heller G, Clarkson B.  Long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alpha. Interferons & Cytokines 1991; 17:16-19.

  12. Berman E, Heller G, Santorsa J, et al.   Results of a randomized trial comparing Idarubicin and Cytosine Arabinoside with Daunorubicin and Cytosine Arabinoside in adult patients with newly diagnosed acute Nonlymplocytic Leukemia. Blood 1991; 77:1666-1674.

  13. Cheung N-KV, Heller G. Dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma.  J Clin Oncol 1991; 9:1050-1058.

  14. Steinhertz LJ, Steinhertz PG, Tan CTC, Heller G, Murphy L.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266:1672-1677.

  15. Warrell RP Jr, Murphy WK, Schulman P, O’Dwyer PJ, Heller G.  A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991; 9:1467-1475.

  16. Heller G, Simonoff J.  Prediction in censored survival data:  A comparison of the proportional hazards and linear regression models. Biometrics 1992; 48:101-115.

  17. LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V, Wollner N, Enker WE, Cohen AM, and Exelby PR.  Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg 1992; 27:1085-1090.

  18. MacKinnon S, Barnett L, Bourhis JH, Black P, Heller G, O’Reilly RJ.  Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of polymerase chain reaction of genomic DNA. Blood 1992; 80:3235-3241.

  19. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marlove R, Vlamis V, Rosen G.   Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan Kettering experience. J Clin Oncol 1992; 10:5-15

  20. Wood DP Jr, Herr HW, Heller G, Vlamis V, Sogani C, Motzer RJ, Fair WR, Bosl GJ.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.  J Urol 1992; 148:1812-1815.

  21. Young JW, Papadopoulos EB, Cunningham I, Castro-Malaspina H, Flomenberg N, Carabasi MH, Gulati SC, Brochstein JA, Heller G, Black P, et al.  T-cell-depleted allogeneic bone marrow transplantation in adults with acute nonlymphocytic leukemia in risk remission. Blood 1992; 71:3380-3387.

  22. Bergman I, Arbit E, Rosenblum M, Larson SM, Heller G, Cheung NKV.   Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. J Neurooncol 1993; 15:235-242.

  23. Chatterjee S, Heller G.  The numerical effect of measurement error in the explanatory variables on the observed least squares estimate. SIAM Journal of Matrix Analysis 1993; 14:677-687.

  24. Kritz A, Brown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG, et al.  Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor.  A randomized trial. Cancer 1993; 71:2515-2521.

  25. Meyers PA, Heller G, Vlamis V. Osteosarcoma of the Extremities:  Chemotherapy Experience at Memorial Sloan Kettering. In:  G. Bennett Humphrey (ed.), Osteosarcoma in Adolescents and Young Adults.  Boston: Kluwer Academic Publishers,  1993:309-322.

  26. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M, LaQuaglia M.   Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11:449-453.

  27. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G.  Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. Cancer 1993; 72:3120-3130.

  28. Steinherz LJ, Steinherz PG, Heller G.  Anthracycline-Related Cardiac Damage, In: Cardiac Toxicity After Treatment of Childhood Cancer. New York: Wiley-Liss Inc, 1993:63-72.

  29. Wollner N, Exelby P, Lindsley KL, Lieberman P, Filippa D, Heller G.  Primary peripheral nodal lymphoma in children. Cancer 1993; 71:3670-3679.

  30. Cheung N-KV, Cheung IY, Canate A, Yeh SJ, Kushner B, Bonilla MA, Heller G, and Larson SM. Antibody response to murine anti-BD2 monoclonal antibodies:  Correlation with patient survival. Cancer Res 1994; 54:2228-2233.

  31. Eardley AM, Heller G, Warrell RP Jr.  Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.  Leukemia 1994; 8:934-939.

  32. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr.  All-trans retinoic acid for acute promyelocytic leukemia.  Results of the New York Study.  Ann Intern Med 1994; 120:278-286.

  33. Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G, Cheung N-KV.  Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.  J Clin Oncol 1994; 12:2607-2613.

  34. LaQuaglia MP, Caldwell C, Lucas A, Carbally M, Heller G, Steinherz L, Brown AE, Groeger J, Exelby PR.  A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J Pediatr Surg 1994; 29:742-745.

  35. LaQuaglia MP, Heller G, Ghavimi F, Casper ES, Vlamis V, Hajdu S, Brennan MF.  The effect of age at diagnosis on outcome in rhabdomyosarcoma.  Cancer 1994; 73:109-117.

  36. MacKinnon S, Barnett L, Heller G, O’Reilly RJ.  Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83:3409-3416.

  37. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR.  Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8:929-933.

  38. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA, Warrell RP Jr.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact and leukocytosis, low-dose chemotherapy, PMN/RAR-α All-trans retinoic acid. Blood 1994; 84:3843-3849.

  39. LaQuaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung N-KV.  Stage 4 Neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome.  J Pediatr Surg 1994; 29:1162-1166.

  40. Boulad F, Bromley M, Black P, Heller G, Sarafoglou K, Gillio A, Papadopoulos E, Sklar C. Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation.  Bone Marrow Transplant 1995; 15:71-76.

  41. Faulkner LB, Hajdu SI, Kher U, LaQuaglia M, Exelby PR, Heller G, Wollner N.  Pediatric desmoid tumor: retrospective analysis of 63 cases.  J Clin Oncol 1995; 13:2813-2818.

  42. Huma Z, Boulad F, Black P, Heller G, Sklar C.  Growth in children after bone marrow transplantation for acute leukemia.  Blood 1995; 86:819-824.

  43. Kushner BH, Meyers PA, Gerald WL, Healey JH, LaQuaglia MP, Boland P, Wollner N, Casper ES, Aledo A, Heller G, et al.  Very- high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults.  J Clin Oncol 1995; 13:2796-2804.

  44. Papadakis V, Diazbarrientos T, Heller G, Collins NH, McKeever S, Kernan NA.  Serum granulocyte colony-stimulating factor (G-CSF) levels after allogeneic T cell-depleted marrow transplantation.  Bone Marrow Transplant 1995; 15:955-961.

  45. Papadakis V, Ferguson KF, Heller G, Kernan NA.  In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-α and IFN-γ.  Exp Hematol 1995; 23:1422-1430.

  46. Wheatley JM, Rosenfield NS, Heller G, Feldstein D, LaQuaglia MP.  Validation of a technique of computer-aided tumor volume determination.  J Surg Res 1995; 59:621-626.

  47. Scaradovou A, Heller G, Sklar C, Ghavimi F.  Second malignant neoplasms in long-term survivors of childhood rhabdomyosarcoma.   Cancer 1995; 76:1860-1867.

  48. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G.  The Identification of Febrile, Neutropenic Children with Neoplastic Disease at Low Risk for Bacteremia and Complications of Sepsis.  Cancer 1996; 77:791-798.

  49. Sahdevi, O’Reilly R, Black P, Heller G, Hoffmann M.  Interleukin-1 Production Following T-Cell-Depleted and Unmodified Marrow Grafts.  Pediatr Hematol Oncol 1996; 13:55-67.

  50. Faulkner LB, Lindsley IL, Kher U, Heller G, Black P, Finlay JL.  High-dose chemotherapy with autologous marrow rescue for malignant brain tumors: analysis of the impact of prior chemotherapy and cranio-spinal irradiation on hematopoietic recovery.  Bone Marrow Transplant 1996; 17:389-394.

  51. MacKinnon S, Barnett L, Heller G.   Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.  Bone Marrow Transplant 1996; 17:643-647.

  52. Oberfield SE, Soranno D, Nirenberg A, Heller G, Allen JC, David R, Levine LS, Sklar CA.  Age at onset of puberty following high-dose central nervous system radiation therapy.  Arch Pediatr Adolescent Med 1996; 150:589-592.

  53. Lucas KG, Small TN, Heller G, Dupont B, O’Reilly RJ.  The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.  Blood 87:2594-2603.

  54. Papadakis V, Tan C, Heller G, Sklar C.  Growth and final height after treatment for childhood Hodgkin disease.  Pediatr Hematol Oncol 1996; 18:272-276.

  55. Heller G, Venkatraman ES.   Resampling procedures to compare two survival distributions in the presence of right censored data.  Biometrics 1996; 52:1204-1213.

  56. Baceda C. Heller G, Rosenblum M, Diez B, Villablanca JG, Kellie S, Maher P, Vlamis V, Walker RW, Leibel S, Finlay J.  Chemotherapy without irradiation - a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial.  The First International Central Nervous System Germ Cell Tumor Study.  J Clin Oncol 1996; 14:2908-2915.

  57. Michel G, Boulad F, Small TN, Black P, Heller G, Castro-Malaspina H, Childs BH, Billio AP, Papadopoulos EB, Young JW, Kernan NA, O’Reilly RJ.  Risk of extramedullary relapse following allogeneic bone marrow transplantation for acute myelogenous leukemia with leukemia cutis.  Bone Marrow Transplant 1997; 20:107-112

  58. Cheung N-K, Heller G, Kushner BH, Liu Chongyuan, Cheung IY.  Detection of metastatic neuroblastoma in bone marrow:  When is routine marrow histology insensitive?  J Clin Oncol 1997; 15:2807-2817.

  59. Soignet S, Fleishauer A, Polyak T, Heller G, Warrell RP.  All-trans-retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia - long term follow-up of the New York study.  Cancer Chemother 1997; 40:S25-29.

  60. Bergman I, Jakacki RI, Heller G, Finlay J.  Treatment of standard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine.  Med Pediatr Oncol 1997; 29:563-567.

  61. Kraus DH, Saenz NC, Gollamudi S, Heller G, Moustaki M, Gardiner S, Gerald WL, Ghavimi F, LaQuaglia MP.  Pediatric Rhabdomyosarcoma of the head and neck.  Am J Surg 1997; 174:556-560.

  62. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, Polyak T, O’Reilly RJ.  Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. Biol Blood Marrow Transplant 1997; 3:65-75.

  63. Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller G, Rosenblum M, Gardner S, Lyden D, Sands S.   Intensive chemotherapy and bone-marrow rescue for young-children with newly-diagnosed malignant brain-tumors.  J Clin Oncol 1998; 16:210-221.

  64. Newman KD, Black T, Heller G, Azizkhan RG, Holcomb GW, Sklar C, Vlamis V, Haase GM, LaQuaglia MP.  Differentiated thyroid-cancer - determinants of disease progression in patients less-than-21 years of age at diagnosis.  A report from the surgical discipline committee of the Childrens Cancer Group.  Ann Surg 1998; 227:533-541.

  65. Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, Sklar C.   Bone mineral density in young adult survivors of childhood cancer.  J Pediatr Hematol Oncol 1998; 20:241-245.

  66. Aledo A, Heller G, Ren L, Gardner S, Dunkel I, McKay SW, Flombaum C, Brown AE.  Septicemia and septic shock in pediatric-patients - 140 consecutive cases on a pediatric hematology-oncology service.  J Pediatr Hematol Oncol 1998; 20:215-221.

  67. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH .  Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan Kettering (T12) Protocol.  J Clin Oncol 1998; 16:2452-2458.

  68. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH.  The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma.  J Bone Joint Surg 1998; 80-A:1020-1033.

  69. Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfeld NS, Abramson SJ, Gerald WL, Small TN, Gillio AP, Gulati SC, O’Reilly RJ, Ghavimi F.  High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing’s sarcoma, and undifferentiated sarcoma. J Clin Oncol 1998; 16:1697-1706.

  70. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, MacKinnon S, Boulad F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O’Reilly RJ, Young JW.  T-cell depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91:1083-1090.

  71. Kushner BH, Heller G, Cheung N-KV, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers PA.  High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.  J Clin Oncol 1998; 16:3016-3020.

  72. Prasad VK, Kernan NA, Heller G, O’Reilly RJ, Yang SY.  DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B Serology and HLA-DRB1.  Blood 1999; 93:399-409.

  73. Cheung NKV, Heller G, Kushner BH, Kramer K.  Detection of neuroblastoma in bone-marrow by immunocytology - is a single marrow aspirate adequate.  Med Pediatr Oncol  1999; 32:84-87.

  74. Gorlick R, Huvos AG, Heller G, Aledo AL, Beardsley GP, Healey JH, Meyers PA.  Expression of HER2/erbB-2 correlates with survival in osteosarcoma.  J Clin Oncol 1999; 17:2781-2788.

  75. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordonca C, Golde DW.  Response of prostate-cancer to anti-HER-2/NEU antibody in androgen-dependent and androgen-independent human xenograft models.  Cancer Res 1999; 59:4743-4758.

  76. Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN, Brochstein JA, Kernan NA, O’Reilly RJ.  Allogeneic bone marrow transplantation versus chemotherapy for the treatment of childhood acute lymphoblastic leukemia in second remission: a single institution study. J Clin Oncol 1999; 17:197-207.

  77. Bergman I, Barmada MA, Heller G, Griffin JA, Cheung NK. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8. Int J Cancer 1999; 82:538-548.

  78. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, Collins N, Gillio A, George D, Jakubowski A, Heller G, Fazzari M, Kernan N, MacKinnon S, Szabolcs P, Young JW, O’Reilly RJ.  Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of age and donor leukocyte infusions. Blood 1999; 93:467-480.

  79. Prasad VK. Kernan NA. Heller G. O’Reilly RJ. Yang SY.  HLA-C disparity between patients and unrelated donors matched for HLA-A, -B, and -DRB1 alleles: impact of serological vs. DNA typing for HLA-A and -B loci. Biol Blood Marrow Transplant 1999; 5:77-85.

  80. Prasad VK. Heller G. Kernan NA. O’Reilly RJ. Yang SY.  The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. Transplant 1999; 68:1044-50.

  81. Scher HI, Heller G.  Clinical states in prostate cancer - toward a dynamic-model of disease progression.  Urology 2000; 55:323-327.

  82. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.  J Clin Oncol 2000; 18:2620-2625.

  83. Fazzari M, Heller G, Scher HI.  The Phase II/III transition - toward the proof of efficacy in cancer clinical trials.  Control Clin Trials 2000; 21:360-368.

  84. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M.   Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.  Nature 2000; 406:82-86.

  85. Kushner BH, Heller G, Kramer K, Cheung N-KV.   Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma.  Cancer 2000; 89:2122-2130.

  86. Cheung NK, Guo HF, Heller G, Cheung IY.  Induction of Ab3 and Ab3’ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000; 6:2653-2660.

  87. Mora J, Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Fazzari M, Heller G, Chen L, Gerald WL.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2000; 2:37-46.

  88. Heller G, Qin J.  Pairwise rank based likelihood for estimation and inference on the mixture proportion.  Biometrics 2001; 57:813-817.

  89. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H.  Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19:44-53.

  90. Cheung NKV, Kushner BH, Laquaglia M, Kramer K, Gollamud. S, Heller G, Gerald W, Yeh S, Finn R, Larson SM.  N7 – a novel multimodality therapy of high-risk neuroblastoma (NB) in children diagnosed over 1 year of age.  Med Pediatr Oncol 2001; 36:227-230.

  91. Morris CD, Gorlick R, Huvos AG, Heller G, Meyers PA, Healey JH.  Human epidermal growth-factor receptor 2 as a prognostic indicator in osteogenic-sarcoma.  Clin Orthop  2001:59-65

  92. Heller G.  The Cox proportional hazards model with a partly linear relative risk function. Lifetime Data Anal 2001; 7:255-277.

  93. Kramer K, Kushner B, Heller G, Cheung NKV.  Neuroblastoma metastatic to the central nervous system – the Memorial Sloan Kettering Cancer Center experience and a literature review.  Cancer 2001; 91:1510-1519.

  94. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, LaQuagli MP.  The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in-vivo, alone with synergistically with all-trans-retinoic acid.  Cancer Res 2001; 61:3591-3594.

  95. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NKV.  Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery.  J Clin Oncol 2001; 19:2821-2828.

  96. Heller G.  An adjustment for a post-randomization variable in the comparison of two treatments for survival.  Stat Med 2001; 20:3475-3485.

  97. Scher H and Heller G.   Picking the winners in a sea of plenty.  Clin Cancer Res 2002; 8:400-404.

  98. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.  17-Allylamino-17-demethogxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002; 8:986-993.

  99. Sklar CA, Mertens AC, Mitby P, Occhiogroso G, Qin J, Heller G, Yasui Y, Robison LL.  Risk of disease recurrence and 2nd neoplasms in survivors of childhood cancer treated with growth hormone – a report from the childhood cancer survivor study.  J Clin Endocrinol 2002; 87:3136-3141.

  100. Verbel DA, Heller G, Kelly WK, Scher HI.  Quantifying the amount of variation in survival explained by prostate-specific antigen.  Clin Cancer Res 2002; 8:2576-2579.

  101. Lewin SR, Heller G, Zhang L, Rodrigues E, Skulsky E, van den Brink MR, Small TN, Kernan NA, O’Reilly RJ, Ho DD, Young JW.  Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood 2002; 100:2235-2242.

  102. Koehne G, Smith KM, Ferguson TL, Williams RY, Heller G, Pamer EG, Dupont B, O’Reilly RJ.  Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors. Blood 2002; 99:1730-1740.

  103. Berman E, Little C, Teschendorf B, Jones M, Heller G.  Financial analysis of patients with newly diagnozed acute myelogenous leukemia on protocol or standard therapy.  Cancer 2002; 95:1064-1070.

  104. Verbel DA, Kelly WK, Smaletz O, Regan K, Curley T, Heller G, Scher HI.  Estimating survival benefit in castrate metastatic prostate cancer – decision making in proceeding to a definitive phase III trial.  Urology 2003; 61:142-144.

  105. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW.  Differential CD52 expression by distinct myeloid dendritic cell subsets – implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft host interactions in transplantation.  Blood 2003; 101:1422-1429.

  106. Koehne G, Doubrovin M, Doubrovin E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, V Ponomarev, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O’Reilly RJ, Larson SM, Tjuvajev JG.   Serial in-vivo imaging of the targeted migration of human HSV-TK transduced antigen specific lymphocytes.  Nat Biotechnol 2003; 21:405-413.

  107. Kattan MW, Heller G, Brennan MF.  A competing-risks nomogram for sarcoma-specific death following local recurrence.  Stat Med 2003; 22:3515-3525.

  108. Enmon R, Yang WH, Ballangrud AM, Solit DB, Heller G, Rosen N, Scher HI, Sgouros G. Combination treatment with 17AAG and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003; 63:8393-8399.

  109. Heller G. Incorporating follow-up time in M-estimation for survival data. Lifetime Data  Analysis 2004;10:51-64.

  110. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK.  The impact of gross total resection on local control and survival in high-risk neuroblastoma.  J Pediatr Surg 2004;39:412-417.

  111. Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR.  Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.  J Clin Oncol 2004; 22:537-56.

  112. Heller G, Venkatraman ES. A nonparametric test to compare survival distributions with covariate adjustment. J R Statist Soc. B 2004; 66 719-733.

  113. Ryan CJ, Zelefsky MJ, Heller G, Regan K, Leibel SA, Scher HI, Kelly WK. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer. Urology 64:90-94.

  114. Petrovic A, Alpdogan O, Willis LM, Eng JM, Greenberg AS, Kappel BJ, Liu C, Murphy GJ, Heller G, van den Brink MRM. LPAM(alpha(4)beta(7) integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2004 103: 1542-1547.

  115. Doubrovina ES, Doubrovin MM, Lee S, Shieh JH, Heller G, Pamer E, O’Reilly RJ.  In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity.  Clin Cancer Res 2004;10:7207-7219.

  116. Brownstein CM, Mertens AC, Mitby PA, Stovall M, Qin J, Heller G, Robison LL, Sklar CA.  Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study.  J Clin Endocrinol Metab 2004;89:4422-4427.

  117. Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, Munz C, Heller G, Young JW. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol. 2004 Aug 15;173 (4):2780-91.

  118. Yuan J, Latouche JB, Reagan JL, Heller G, Riviere I, Sadelain M, Young JW.  Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.  J Immunol. 2005;174:758-66.

  119. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O’Reilly RJ, Horowitz MM, Dupont B.  Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes.  Blood 2005;105:4878-4884.

  120. Beekman K, Morris M, Slovin S, Heller G, Wilton A, Bianco F Jr. Scardino PT, Scher HI.  Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.  Urology 2005;65:947-952.

  121. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI.  Flurodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.  Clin Cancer Res 2005;11:3210-3216.

  122. Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, VandenBrink MR.  Absence of inducible costimulator on alloreactive T cells reduces graft-versus-host disease and induces Th2 deviation.  Blood  2005; 106:3285-3292.

  123. Boruchov, AM, Heller G, Veri MC, Bovini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions.  J. Clin Invest. 2005 Oct; 115(10):2914-23.

  124. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: “RECIST” ing a step backwards. Clin Cancer Res. 2005 Jul 15;11 (14):5223-32.

  125. Terwey TH, Kim TD, Kochman AA, Hubbard VM, Lu S, Zakrzewski JL, Ramirez-Montagut T, Eng JM, Muriglan SJ, Heller G, Murphy GF, Liu C, Budak-Alpdogan T, Alpdogan O, van den Brink MR. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005 Nov 1;106(9):3322-30.

  126. Beekman KW, Fleming MT, Scher HI, SLovin SF, Ishill NM, Heller G, Kelly WK. Second-line chemptherapy for prostate cancer; patient characteristics and survival. Clin Prostate Cancer. 2005 Sep;4(2):86-90.

  127. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005 92: 965-970

  128. Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-verusu-host disease model. Blood. 2006 Mar 1;107(5): 2045-51.

  129. Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brinnk MR. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006 Feb 15;107(4):1703-11.

  130. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8669-73.

  131. Yuan J, Latouche JB, Hodges J, Houghton AN, Heller G, Sadelain M, Riviere I, Young JW. Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. J Immunol. 2006 Feb 15;176(4):2357-65.

  132. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006 May 11;354(19):2006-13.

  133. Heller G. Power Calculations for Preclinical Studies using a K-sample rank test and the Lehmann Alternative Hypothesis.  Statistics in Medicine 2006 25:2543-2553.

  134. Perales MA, Diab A, Cohen AD, Huggins DW, Guevara-Patino JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MR.  DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation..  J Immunol. 2006 Sep 15;177(6):4159-67.

  135. Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zuniga-Pflucker JC, Alpdogan O, van den Brink MR.  Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.. Nature Medicine 2006 Sep: 12(9) 1039-47.

  136. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA.  Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol Metab 2006 Sep: 91(9):3494-8.

  137. Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol. 2006 Dec;3(12):658-67.

  138. Feltquate D, Nordquist L, Eitcher C, Morris M, Smaletz O, Slovin S, Curley T, Wilton A, Fleisher M, Heller G, Scher HI. Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer. Clinical Cancer Research. 2006:15;7414-7421.

  139. Scher H, Warren M, Heller G, The association between measures of progression and survival in castrate-metastatic prostate cancer. Clinical Cancer Research 2007:13;1488-1492.

  140. Heller G, Kattan M, Scher H, Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy. Medical Decision Making 2007; 27:380-386.

  141. Heller G, Smoothed rank regression with censored data. Journal of American Statistical Association 2007:102;552-559.

  142. Yuan J, Kendle R, Ireland J, Heller G, Sadelain M, Young JW, Rivere I. Scalable expansion of potent genetically modified human Langerhans cells in a closed system for clinical applications. Journal of Immunotherapy. 2007; 30:634-643.

  143. Ramirez-Montagut T, Chow A, Kochman AA, Smith OM, Suh D, Sindhi H, Lu S, Borsotti C, Grubin J, Patel N, Terwey TH, Kim TD, Heller G, Murphy GF, Liu C, Alpodogan O, van den Brink MR. IFN-gamma and Fas ligand are required for graft versus tumor activity against renal cell carcinoma in the absence of lethal graft versus host disease. Journal of Immunology. 2007; 179:1669-1680.

  144. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O’reilly RJ, Small TN, Young JW, Kernan NA. Long-term follow-up of patients treated with Daclizumab for steroid –refractory acute graft-versus-host disease. 2007;40:481-486.

  145. Heller G, Qin J. Inference on the limiting false discovery rate and the p-value threshold parameter assuming weak dependence between gene expression levels within subject. Statistical Applications in Genetics and Molecular Biology. 2007: 6:Article 14.

  146. Chemaitilly W, Boulad F, Heller G, Kernan N, Small TN, O’Reilly RJ, Sklar CA. Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation. Bone Marrow Transplant. 2007; 40:29-35.

  147. Shaffer DR, Leversha MA, Danilla DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer. Clinical Cancer Research 2007:13;2023-2029.

  148. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clinical Cancer Research. 2007:13;1783-1788.

  149. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clinical Cancer Research 2007:13;1775-1782.

  150. Small TN, Young JW, Castro-Malaspina H, Prockop S, Wilton A, Heller G, Boulad F, Chiu M, Hsu K, Jakubowski A, Kernan NA, Perales MA, O’Reilly RJ, Papadopoulos EB. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biology Blood Marrow Transplant. 2007:3;235-44.

  151. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E,  Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.. Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer.Clin Cancer Res. 2007 Dec 1;13(23):7053-7058.

  152. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M.T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.Nat Med. 2007 Dec;13(12):1440-1449.

  153. Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MR, Young JW, Prockop SE, Collins NH, O’Reilly RJ, Boulad F. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.Biol Blood Marrow Transplant. 2007 Nov;13(11):1313-23.

  154. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.J Immunol. 2007 Nov 1;179(9):5977-89.

  155. Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.J Urol. 2007 Dec;178(6):2378-83.

  156. Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008  113:966-74.

  157. Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI.  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008 Jun 20;26(18):2959-65.

  158. Zakrzewski JL, Suh D, Markley JC, Smith OM, King C, Goldberg GL, Jenq R, Holland AM, Grubin J, Cabrera-Perez J, Brentjens RJ, Lu SX, Rizzuto G, Sant’Angelo DB, Riviere I, Sadelain M, Heller G, Zúñiga-Pflücker JC, Lu C, van den Brink MR.  Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008 Apr;26(4):453-61.

  159. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20;26(9):1472-8.

  160. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O’Reilly RJ.  Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant. 2008 Apr;14(4):458-68.

  161. Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A, Heller G, Wolden S, O’Reilly RJ, Boulad F. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol. 2008 Mar;140(6):644-55.

  162. Kim TD, Terwey TH, Zakrzewski JL, Suh D, Kochman AA, Chen ME, King CG, Borsotti C,   Grubin J, Smith OM, Heller G, Liu C, Murphy GF, Alpdogan O, van den Brink MR.  Organ-derived dendritic cells have differential effects on alloreactive T cells. Blood. 2008 Mar 1;111(5):2929-40.

  163. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, Holland AM, Grubin J, Mark NM, Liu C, Iwakura Y, Heller G, van den Brink MR. IL-17 contributes to CD4-mediated graft-versus-host disease.  Blood. 2009 Jan 22;113(4):945-952.

  164. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009 Mar;10(3):233-9. Epub 2009 Feb 11 [PubMed Abstract]

  165. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A,  Lilja H, Heller G, Fleisher M, Scher HI. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009 Mar 15;15(6):2091-7. Epub 2009 Mar 10.

  166. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O’Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20;27(15):2436-42. Epub 2009 Apr 13.  [PubMed Abstract]

  167. Barker JN, Abboud M, Rice RD, Hawke R, Schaible A, Heller G, La Russa V, Scaradavou A. A “no-wash” albumin-dextran dilution strategy for cord blood unit thaw: high rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1596-602. Epub 2009 Sep 25.

  168. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. Epub 2009 Nov 17.  [PubMed Abstract]

  169. Patel KJ, Rice RD, Hawke R, Abboud M, Heller G, Scaradavou A, Young JW, Barker JN. Pre-Engraftment Syndrome after Double Unit Cord Blood Transplantation: A Distinct Syndrome not Associated with Acute Graft-Versus-Host Disease.  Biology of Blood and Marrow Transplant. 16:35-40.  2010

  170. Sima CS, Panageas KS, Heller G, Schrag D. Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Applied Health Econ Health Policy.  8:37-51. 2010

  171. Penack O, Henke E, Suh D, King CG, Smith OM, Na IK, Holland AM, Ghosh A, Lu SX, Jenq RR, Liu C, Murphy GF, Lu TT, May C, Scheinberg DA, Gao DC, Mittal V, Heller G, Benezra R, van den Brink MR. Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth. Journal of the National Cancer Institute. 102: 894-908.  2010

  172. Gönen M, Heller G. Lehmann Family of ROC Curves. Medical Decision Making.  30: 509-517. 2010.

  173. Bhandari S, Cheung NK, Kushner BH, Kramer K, Modak S, Larson SM, Yeh S, Heller G, Sklar CA. Hypothyroidism after (131)I-monoclonal antibody treatment of neuroblastoma. Pediatr Blood Cancer.  55:76-80.  2010

  174. Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O’Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant.  45:1408-1416.  2010

  175. Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, Wells DS, Heller G, Papadopoulos EB, Scaradavou A, Young JW, van den Brink MR. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant. 16:1541-8.  2010.

  176. Eldjerou LK, Chaudhury S, Baisre-de Leon A, He M, Arcila ME, Heller G, O’Reilly RJ, Barker JN, Moore MA. An in vivo model of double unit cord blood transplantation that correlates with clinical engraftment. Blood.  116:3999-4006. 2010.

  177. Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Barker JN.  Influence of infused cell dose and HLA-match on engraftment after double-unit cord blood allografts. Blood. 2011 Mar24;117(12):3277-85. [PubMed Abstract]

  178. Heller G. Proportional hazards regression with interval censored data using an inverse probability weight.  Lifetime Data Analysis. 17:373-385. 2011.

  179. Hanash AM, Kappel LW, Yim NL, Nejat RA, Goldberg GL, Smith OM, Rao UK, Dykstra L, Na IK, Holland AM, Dudakov JA, Liu C, Murphy GF, Leonard WJ, Heller G, van den Brink MR. Abrogation of donor T cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011 May 20. [Epub ahead of print] [PubMed Abstract]

  180. Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN. Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin. Biol Blood Marrow Transplant. 2011 Mar 1. [Epub ahead of print] [PubMed Abstract]

  181. Ponce DM, Zheng J, Gonzales AM, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O’Reilly RJ, Barker JN. Reduced Late Mortality Risk Contributes to Similar Survival after Double-Unit Cord Blood Transplantation Compared with Related and Unrelated Donor Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2011 Jan 11. [Epub ahead of print] [PubMed Abstract]

  182. Heller G. A measure of explained risk in the proportional hazards model. Biostatistics 2011 Dec 21 [Epub ahead of print]

  183. Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchock JD,Houghton AN, Chapman PB, Heller G, Yuan J, Young JW. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res. 2011 Apr 1;17(7):1984-97. Epub 2011 Feb 25. [PubMed Abstract]

  184. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011 Apr 15;71(8):2871-81. Epub 2011 Apr 12. [PubMed Abstract]

  185. Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R, Knowles MA, Papadopoulos EB, Casson A, Copeland C, Torok-Castanza J, Zakak N, Ruggiero J, Small TN. Safety and Immunogenicity of the Live Attenuated Varicella Vaccine following T Replete or T Cell-Depleted Related and Unrelated Allogeneic Hematopoietic Cell Transplantation (alloHCT). Biol Blood Marrow Transplant. 2011  May 23. [Epub ahead of print] [PubMed Abstract]

  186. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29(16):2191–2198.

  187. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011;29(27):3695–3704.

  188. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30 (5):519-24. PMCID: PMC3295554.

  189. Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O’Reilly RJ. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012 Mar 15; 119 (11):2644-56. PMCID: PMC3311278.

  190. Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, Schwartz LH, Curley T, DeLaCruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol. 2012 Apr; 69 (4):1089-97.

  191. Heller G. A measure of explained risk in the proportional hazards model. Biostatistics. 2012 Apr; 13 (2):315-25. PMCID: PMC3297826.

  192. Ponce DM, Lubin M, Gonzales AM, Byam C, Wells D, Ferrante R, Heller G, Giralt S, Papadopoulos EB, Kernan NA, Scaradavou A, Barker JN. The use of back-up units to enhance the safety of unrelated donor cord blood transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18 (4) :648-51. PMCID: PMC3303962.

  193. Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, Fink MJ, St Angelo ET, Mehrara B, Heller G, Münz C, Altan-Bonnet G, Young JW. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood. 2012 May 31; 119 (22):5182-90. PMCID: PMC3369609.

  194. Honeyman JN, Rich BS, McEvoy MP, Knowles MA, Heller G, Riachy E, Kobos R, Shukla N, Wolden SL, Steinherz PG, La Quaglia MP. Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. J Pediatr Surg. 2012 Jun; 47 (6):1228-33.

  195. Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012 Sep 4;122(9):3260-70. PMCID: PMC3428088

  196. Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O’Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA. T Cell-Depleted Stem Cell Transplantation for Adults with High-Risk Acute Lymphoblastic Leukemia: Long-Term Survival for Patients in First Complete Remission with a Decreased Risk of Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2012 Sep 13.

  197. Choudhary A, Chou J, Heller G, Sklar C. Prevalence of vitamin D insufficiency in survivors of childhood cancer. Pediatr Blood Cancer. 2012 Nov 28.


My Pages